Oncology Cash Conversion Cycle from 2010 to 2026

TOI Stock  USD 3.58  0.00  0.00%   
Oncology Institute's Cash Conversion Cycle is increasing with slightly volatile movements from year to year. Cash Conversion Cycle is predicted to flatten to 24.87. For the period between 2010 and 2026, Oncology Institute, Cash Conversion Cycle quarterly trend regression had mean deviation of  7.51 and range of 44.7393. View All Fundamentals
 
Cash Conversion Cycle  
First Reported
2010-12-31
Previous Quarter
26.82
Current Value
24.87
Quarterly Volatility
11.33144475
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Oncology Institute financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncology Institute's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 4.3 M or Interest Expense of 9.1 M, as well as many indicators such as Price To Sales Ratio of 0.0644, Dividend Yield of 0.0105 or PTB Ratio of 9.87. Oncology financial statements analysis is a perfect complement when working with Oncology Institute Valuation or Volatility modules.
  
Build AI portfolio with Oncology Stock
Check out the analysis of Oncology Institute Correlation against competitors.
For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.

Latest Oncology Institute's Cash Conversion Cycle Growth Pattern

Below is the plot of the Cash Conversion Cycle of Oncology Institute over the last few years. It is Oncology Institute's Cash Conversion Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncology Institute's overall financial position and show how it may be relating to other accounts over time.
Cash Conversion Cycle10 Years Trend
Slightly volatile
   Cash Conversion Cycle   
       Timeline  

Oncology Cash Conversion Cycle Regression Statistics

Arithmetic Mean24.64
Geometric Mean22.98
Coefficient Of Variation45.99
Mean Deviation7.51
Median20.07
Standard Deviation11.33
Sample Variance128.40
Range44.7393
R-Value0.45
Mean Square Error109.17
R-Squared0.20
Significance0.07
Slope1.01
Total Sum of Squares2,054

Oncology Cash Conversion Cycle History

2026 24.87
2025 26.82
2024 29.8
2023 47.27
2022 58.25
2021 17.67
2020 13.51

About Oncology Institute Financial Statements

Investors use fundamental indicators, such as Oncology Institute's Cash Conversion Cycle, to determine how well the company is positioned to perform in the future. Although Oncology Institute's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Cash Conversion Cycle 26.82  24.87 

Currently Active Assets on Macroaxis

When determining whether Oncology Institute offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncology Institute's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncology Institute Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncology Institute Stock:
Check out the analysis of Oncology Institute Correlation against competitors.
For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.67)
Revenue Per Share
5.279
Quarterly Revenue Growth
0.215
Return On Assets
(0.17)
Return On Equity
(6.52)
The market value of Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.